Advertisement
ARVN vs STOK
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARVN is a Hold and STOK is a Hold.
ARVN's Indicator enters downward trend
The Aroon Indicator for ARVN entered a downward trend on October 23, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 261 similar instances where the Aroon Indicator formed such a pattern. In 235 of the 261 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ARVN as a result. In 73 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for ARVN turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 37 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARVN's RSI Indicator exited the oversold zone, 26 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 55 cases where ARVN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
Following a +7.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where ARVN advanced for three days, in 200 of 251 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
ARVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 73 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ARVN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (3.498). P/E Ratio (21.367) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (1.733) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ARVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
STOK in upward trend: price rose above 50-day moving average on November 13, 2026
STOK moved above its 50-day moving average on November 13, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 40 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where STOK's RSI Indicator exited the oversold zone, 23 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 13, 2026. You may want to consider a long position or call options on STOK as a result. In 72 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for STOK just turned positive on October 15, 2026. Looking at past instances where STOK's MACD turned positive, the stock continued to rise in 39 of 46 cases over the following month. The odds of a continued upward trend are 85%.
The 10-day moving average for STOK crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +6.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where STOK advanced for three days, in 269 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
STOK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 215 of 254 cases where STOK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 56 of 67 cases where STOK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STOK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.956) is normal, around the industry mean (3.498). P/E Ratio (-7.829) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (63.291) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 52 (best 1 - 100 worst), indicating steady price growth. STOK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 88 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STOK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
ARVN | STOK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 86 Overvalued | 28 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 88 | |
SMR RATING 1..100 | 83 | 98 | |
PRICE GROWTH RATING 1..100 | 73 | 52 | |
P/E GROWTH RATING 1..100 | 73 | 98 | |
SEASONALITY SCORE 1..100 | n/a | 24 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
STOK's Valuation (28) in the null industry is somewhat better than the same rating for ARVN (86) in the Biotechnology industry. This means that STOK’s stock grew somewhat faster than ARVN’s over the last 12 months.
STOK's Profit vs Risk Rating (88) in the null industry is in the same range as ARVN (100) in the Biotechnology industry. This means that STOK’s stock grew similarly to ARVN’s over the last 12 months.
ARVN's SMR Rating (83) in the Biotechnology industry is in the same range as STOK (98) in the null industry. This means that ARVN’s stock grew similarly to STOK’s over the last 12 months.
STOK's Price Growth Rating (52) in the null industry is in the same range as ARVN (73) in the Biotechnology industry. This means that STOK’s stock grew similarly to ARVN’s over the last 12 months.
ARVN's P/E Growth Rating (73) in the Biotechnology industry is in the same range as STOK (98) in the null industry. This means that ARVN’s stock grew similarly to STOK’s over the last 12 months.
| ARVN | STOK | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 84% | 3 days ago 85% |
| Stochastic ODDS (%) | 3 days ago 82% | 3 days ago 84% |
| Momentum ODDS (%) | 3 days ago 79% | 3 days ago 88% |
| MACD ODDS (%) | 3 days ago 80% | 3 days ago 85% |
| TrendWeek ODDS (%) | 3 days ago 78% | 3 days ago 85% |
| TrendMonth ODDS (%) | 3 days ago 77% | 3 days ago 82% |
| Advances ODDS (%) | 6 days ago 80% | 7 days ago 88% |
| Declines ODDS (%) | 3 days ago 81% | 17 days ago 85% |
| BollingerBands ODDS (%) | 3 days ago 79% | 4 days ago 88% |
| Aroon ODDS (%) | 3 days ago 90% | 3 days ago 85% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ARVN’s FA Score shows that 0 FA rating(s) are green while STOK’s FA Score has 1 green FA rating(s).
- ARVN’s FA Score: 0 green, 5 red.
- STOK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ARVN’s TA Score shows that 4 TA indicator(s) are bullish while STOK’s TA Score has 8 bullish TA indicator(s).
- ARVN’s TA Score: 4 bullish, 4 bearish.
- STOK’s TA Score: 8 bullish, 2 bearish.
Price Growth
ARVN (@Biotechnology) experienced а +6.40% price change this week, while STOK (@Biotechnology) price change was +0.53% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.38%. For the same industry, the average monthly price growth was -5.88%, and the average quarterly price growth was -18.27%.
Reported Earning Dates
ARVN is expected to report earnings on Mar 01, 2027.
STOK is expected to report earnings on Mar 16, 2027.
Industries' Descriptions
@Biotechnology (-3.38% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ARVN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ARVN has been loosely correlated with BCYC. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ARVN jumps, then BCYC could also see price increases.
| Ticker / NAME | Correlation To ARVN | 1D Price Change % | ||
|---|---|---|---|---|
| ARVN | 100% | -0.73% | ||
| BCYC - ARVN | 47% Loosely correlated | -2.32% | ||
| OLMA - ARVN | 46% Loosely correlated | +0.53% | ||
| AXON - ARVN | 46% Loosely correlated | +2.71% | ||
| VCYT - ARVN | 46% Loosely correlated | -1.22% | ||
| STOK - ARVN | 46% Loosely correlated | +1.83% | ||
More | ||||
STOK and
Correlation & Price change
A.I.dvisor indicates that over the last year, STOK has been loosely correlated with DYN. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then DYN could also see price increases.
| Ticker / NAME | Correlation To STOK | 1D Price Change % | ||
|---|---|---|---|---|
| STOK | 100% | +1.83% | ||
| DYN - STOK | 54% Loosely correlated | +0.88% | ||
| RCKT - STOK | 53% Loosely correlated | -3.77% | ||
| TSHA - STOK | 51% Loosely correlated | -2.61% | ||
| SLDB - STOK | 51% Loosely correlated | -2.29% | ||
| EDIT - STOK | 50% Loosely correlated | +1.40% | ||
More | ||||